Mark M. Levinson

Cardiac transplantation in patients over 50 years of age

Sixty-two patients underwent cardiac transplantation at the University of Arizona from March 1979 to March 1985. Thirteen patients (11 men and 2 women) were over 50 years of age at the time of transplantation and 49 were under the age of 50. The mean age (+/- SEM) of the patients over 50 was 53 +/- 1 years. Eight of these patients were treated with conventional immunosuppressive therapy (azathioprine, prednisone and rabbit antithymocyte globulin) and five, beginning in January 1983, were treated with cyclosporine, prednisone and rabbit antithymocyte globulin. Early mortality (0 to 90 days) was 16% in the group over 50 versus 18% for those under 50. The late mortality (greater than 90 days) was 36 and 33%, respectively. In both groups, rejection and infection were the principal causes of death. The incidence of infection was 1.9 +/- 0.5 episodes per patient in those patients over 50 and 1.9 +/- 0.4 in those under 50. The incidence of rejection was 1.3 episodes per patient-year in patients over 50 and 1.7 episodes per patient-year in those under 50. Actuarial survival at 1 year was 72 +/- 14% in the group over 50 and 66 +/- 7% in the group under 50 years of age. These data indicate that the results of cardiac transplantation for patients over 50 do not differ significantly from those for patients under 50. Therefore, it is concluded that a rigidly defined age criterion for cardiac transplant recipients is not acceptable. Each potential recipient must be evaluated in terms of individual risk and benefit from the procedure.

The Cardiac Donor: A Six-Year Experience

From March 1, 1979, to March 1, 1985, the University of Arizona received 223 cardiac donor referrals. Sixty-two were accepted: 15 local, 23 regional (less than 370 km or 200 nautical miles), and 24 distant (370 to 1556 km or 200 to 840 nautical miles). Thirty-eight donor deaths were due to motor vehicle accidents, 10 to gunshot wounds, 6 to cerebral disease, and 8 to other closed-head lesions. The mean time from injury to brain death was 65 +/- 5 hours (+/- standard error of the mean [SEM]) and from brain death to organ donation, 12 +/- 3 hours. The mean ischemic time for the donor hearts ranged from 30 to 233 minutes (mean +/- SEM, 128 +/- 7 minutes). Fifty patients, otherwise acceptable, were refused as cardiac donors because an ABO-compatible recipient was not available. Two regionally procured hearts failed at operation, 1 because of unrecognized donor sepsis and 1 from a patient on large-dose inotropic support. Although there was no difference in myocardial function, median survival with follow-up through June 30, 1985, of patients receiving locally, regionally, and distantly procured organs was 59 months, 18 months, and 21 months, respectively. Cumulative proportion 1-year survival was 93%, 56%, and 61%, respectively. The 2-year survival was 85% for patients given locally procured hearts, 43% for those with regionally procured hearts, and 38% for those with a heart from a distant donor. Survival curves showed significantly longer survival for locally procured organs than regionally or distantly procured organs (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Gastrointestinal complications after human transplantation and mechanical heart replacement

One hundred fifty-three patients underwent 159 heart transplants; 7 of these patients received 8 artificial hearts used as a bridge before implantation. The 1-year survival rate was 81 percent. One hundred forty gastrointestinal complications developed in 70 patients. Thirty-eight operations were required. Twenty-nine were intraabdominal operations. Of these, 22 were elective and 7 were emergency procedures. Five of the seven patients who underwent emergency procedures died, for an overall total mortality rate of 17 percent for major intraabdominal interventions. There were no complications or deaths in patients who underwent elective procedures. Major elective intraabdominal surgical interventions can be safely carried out in heart transplant patients. Repeated physical examination, aggressive use of endoscopy and imaging techniques, sound surgical judgement and a mutual relationship of trust and respect between cardiac and general surgeons are keys to a successful outcome.

Use of Pericardial Fat Pad Flap to Prevent Bronchopleural Fistula

Use of the pericardial fat pad flap to cover the bronchial stump following pulmonary resection can minimize the occurrence of bronchopleural fistula, a serious complication. The surgical technique as shown is safe and easily accomplished.

Technical Aspects of Total Artificial Heart Implantation For Temporary Applications

Temporary use of the Jarvik‐7 artificial heart in critically ill patients awaiting transplantation has prevented death in > 60% of attempts. Success is very dependent on meticulous surgical technique. Failures in the operating room cascade into enlarging problems postoperatively. Appropriately selected patients implanted without bleeding or fit problems recover quickly and are suitable candidates for transplantation within a few days. Even acute renal failure or pulmonary insufficiency from end‐stage cardiac disease rapidly reverses upon restoration of normal hemodynamics. Anticoagulation is mandatory to prevent thromboembolism and continuous heparin plus oral dipyridamole is the most successful regimen to date. Primary intraoperative security of all suture lines or potential bleeding foci is thus essential. Bleeding has been associated with tamponade, pulmonary complications, and transfusion stimulated anti‐HLA antibodies which can prevent subsequent transplantation. The length and suturing technique of the aortic conduit are critical. Compression of the mediastinal structures by the device can impede systemic or pulmonary venous return, with disastrous results. Displacement of the blood pumps away from the midline, usually into the pleural space, allows for more room when closing the sternum. The 100 cc blood pump fits best in patients > 85 kg, while the 70 cc model can be implanted in patients as small as 50–60 kg.